In the case of a CF mother and CF baby or non-CF mother and CF baby, it is unclear if CFTR modulators before birth would confer even greater benefits by correcting mutations in utero for at-risk organs before pulmonary and extrapulmonary complications arise. This evidence concerns the gene CFTR and cystic fibrosis.